Abstract
The prevalence of diseases such as AML or myelodysplastic syndromes increases with the aging of the population. Only intensive chemotherapy or hematopoietic cell transplantation have curative potential. However, comorbid conditions may interfere with effective therapy. Although transplantation following low-intensity conditioning is being carried out in patients even in their 70s, these are highly selected patients, and the data cannot be extrapolated to the population at large. Further, such a therapy in older individuals may be associated with considerable morbidity and the need for prolonged hospitalization and rehabilitation, stressing the system and draining family resources. As the focus of many older individuals is on quality of life, it is important to emphasize that, for various advanced malignancies, emerging data indicate that quality of life may be better and survival may be longer with palliative care. A re-assessment of treatment decisions in older patients is in order. We tend to 'oversell', and particularly older patients do not have a full understanding of the impact of the proposed therapy on their lives. Our conversations with these patients must include a discussion of supportive/palliative care and must address end-of-life issues. Talking about death may mean talking about life.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Deeg HJ, Steuten LM . Therapy for hematologic malignancies in older patients, quality of life and health economics - difficult decisions. JAMA Oncol, in press.
WHO. WHO Global Health Observatory Data Repository. 2014.
Fillit HM, Rockwood K, Woodhouse K . Brocklehurst's Textbook of Geriatric Medicine and Gerontology: Expert Consult. Elsevier Health Sciences: Philadelphia, PA, USA, 2010.
Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Pardee TS et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 2013; 121: 4287–4294.
Shinn EH, Lenihan DJ, Urbauer DL, Basen-Engquist KM, Valentine A, Palmero L et al. Impact of cardiovascular comorbidity on ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev 2013; 22: 2102–2109.
Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB et al. Comorbidity-age index: a clinical measure of biological age before allogeneic hematopoietic cell transplantation. J Clin Oncol 2014; 32: 3249–3256.
Bordessoule D . Vulnerbility in hematology. Hématologie 2013; 19: 50–68.
Campisi J . Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors (Review). Cell 2005; 120: 513–522.
Ossenkoppele G, Lôwenberg B . How I treat the older patient with acute myeloid leukemia. Blood 2014; 125: 767–774.
Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481–3485.
Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J et al. Conditioning with fludarabine and targeted busulfan before transplantation of allogeneic hematopoietic stem cells. Blood 102: 820–826.
Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A et al. Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report. J Clin Oncol 2015; 33: 1157–1164.
Ostronoff F, Othus M, Ho PA, Kutny M, Geraghty DE, Petersdorf SH et al. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report (Letter to the Editor). Leukemia 2013; 27: 238–241.
Stirewalt DL, Kopecky KJ, Meshinchi S, Engel JH, Pogosova-Agadjanyan EL, Linsley J et al. Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood 2006; 107: 3724–3726.
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120: 2454–2465.
Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 2008; 22: 538–543.
Ostronoff F, Estey E . The role of quizartinib in the treatment of acute myeloid leukemia. Expert Opin Investig Drugs 2013; 22: 1659–1669.
Mims A, AR Walker, Huang X, Sun J, Wang H, Santhanam R et al. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia 2013; 27: 871–878.
Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011; 306: 1874–1883.
Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol 2013; 31: 2662–2670.
Flowers MED, Deeg HJ . Chronic graft-versus-host disease. In: Treleaven J, Barrett AJ (eds). Hematopoietic Stem Cell Transplantation in Clinical Practice. Elsevier Ltd: Edinburgh, UK, 2009, pp 401–407.
Khera N, Storer B, Flowers ME, Carpenter PA, Inamoto Y, Sandmaier BM et al. Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol 2012; 30: 71–77.
Gawande A . Being Mortal: Medicine and What Matters in the End. Henry Holt and Company: New York, NY, USA, 2014.
Quill TE, Arnold R, Back AL . Discussing treatment preferences with patients who want "everything". Ann Intern Med 2009; 151: 345–349.
Zaner RM . Troubled Voices; Stories of Ethics and Illness. The Pilgrim Press: Cleveland, OH, USA, 1993.
Rhodes R . Rethinking research ethics. Am J Bioeth 2005; 5: 7–28.
Taylor WD . Clinical practice. Depression in the elderly (Review). N Engl J Med 2014; 371: 1228–1236.
Parimon T, Au DH, Martin PJ, Chien JW . A risk score for mortality after allogeneic hematopoietic cell transplantation. Ann Intern Med 2006; 144: 407–414.
Sorror M . How I assess comorbidities prior to hematopoietic cell transplantation. Blood 2013; 121: 2854–2863.
Bach PB . Indication-specific pricing for cancer drugs. JAMA 2014; 312: 1629–1630.
National Center for Health Statistics Health, United States, 2013: With Special Health, United States, 2013: With Special Feature on Prescription Drugs. Department of Health and Human Services, Centers for Disease Control and Prevention: Hyattsville, MD, USA, 2014.
Centers for Medicare & Medicaid Services National Health Expenditure Data. Research, Statistics, Data & Systems: Washington DC, WA, USA, 2014.
Fuchs VR . How and why US health care differs from that in other OECD countries. JAMA 2013; 309: 33–34.
Baicker K, Levy H . The insurance value of Medicare. N Engl J Med 2012; 367: 1773–1775.
Ballen KK, Gilliland DG, Guinan EC, Hsieh CC, Parsons SK, Rimm IJ et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant 1997; 20: 737–743.
Back A, Arnold R, Tulsky J . Mastering Communication with Seriously Ill Patients: Balancing Honesty with Empathy and Hope. Cambridge University Press: Cambridge, MA, USA, 2009.
Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733–742.
Partridge AH, Seah DS, King T, Leighl NB, Hauke R, Wollins DS et al. Developing a service model that integrates palliative care throughout cancer care: the time is now. J Clin Oncol 2014; 32: 3330–3336.
Miller VA, Cousino M, Leek AC, Kodish ED . Hope and persuasion by physicians during informed consent. J Clin Oncol 2014; 32: 3229–3235.
Zittoun R . La mort de l'autre. Dunod: Paris, 2007.
WHO - France WHO website: 2015; http://www.who.int/countries/fra/en/.
Fuchs VR . Critiquing US health care. JAMA 2014; 312: 2099–2100.
Back AL, Trinidad SB, Hopley EK, Edwards KA . Reframing the goals of care conversation: "we're in a different place". J Palliat Med 2014; 17: 1019–1024.
Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091–2101.
Obermeyer Z, Makar M, Abujaber S, Dominici F, Block S, Cutler DM . Association between the medicare hospice benefit and health care utilization and costs for patients with poor-prognosis cancer. JAMA 2014; 312: 1888–1896.
Fuchs VR . Current challenges to academic health centers. JAMA 2013; 310: 1021–1022.
Jagsi R . Debating the oncologist's role in defining the value of cancer care: we have a duty to society. J Clin Oncol 2014; 32: 4035–4038.
Acknowledgements
I would like to thank my colleagues at the Fred Hutchinson Cancer Research Center and at several centers in France, which I visited during a recent sabbatical, for their comments. I would like to thank in particular Drs Scott Ramsey, Tony Back, Karen Syrjala, Nandita Khera, Robert Zittoun, Jean-Francois Schved, Mohamad Mohty, Jean-Luc Harousseau, Pierre Fenaux, Lionel Ades, Elie Azoulaye, Gerard Socie, Mike Mullarkey, Fred Tubridy and Jim Miller. I appreciate the help of Helen Crawford and Bonnie Larson with manuscript preparation This study was supported by the National Cancer Institute, National Institutes of Health, Bethesda, MD (CA018029, CA015704, CA078902).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no conflict of interest.
Rights and permissions
About this article
Cite this article
Deeg, H. Treatment ethics, quality of life and health economics in the management of hematopoietic malignancies in older patients. Bone Marrow Transplant 50, 1145–1149 (2015). https://doi.org/10.1038/bmt.2015.130
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2015.130
This article is cited by
-
Palliative and End-of-Life Care in Myelodysplastic Syndromes
Current Hematologic Malignancy Reports (2016)